Vijaya Diagnostic Centre (VIJAYA) Q4 23/24 earnings summary

Executive summary

• FY24 revenue from operations rose 19.3% to ₹54,780.53 lakh consolidated; PAT increased to ₹11,963.71 lakh from ₹8,520.70 lakh.

• Activity expanded to 11.89 million tests and 3.55 million patient visits; the network reached 145 centres and 21 reference laboratories across 23 cities.

• Growth combined new hubs and the December acquisition of PH Diagnostics, extending the footprint into Pune and Western India.

Financial highlights

• Consolidated revenue from operations was ₹54,780.53 lakh vs ₹45,922.27 lakh; total income was ₹56,862.33 lakh vs ₹47,337.34 lakh.

• Consolidated PAT reached ₹11,963.71 lakh vs ₹8,520.70 lakh; basic EPS was ₹11.62 vs ₹8.29.

• PBT was ₹15,868.09 lakh after ₹205 lakh of acquisition-related costs; PBT before exceptional items was ₹16,073.09 lakh.

• Operating cash flow was ₹18,330.09 lakh; net cash used in investing activities was ₹14,230.73 lakh, including the subsidiary acquisition.

• EBITDA was ₹2,209 million, up 21.4% YoY, with a 40.3% margin; PAT growth was 40.4% as reported in the MD’s review.

Outlook and guidance

• Plan to add 10 hub centres over the next two years, emphasizing Pune and Eastern India; funding expected from internal accruals and existing cash reserves.

• Priorities include consolidating recent acquisitions, densifying the network and pursuing potential inorganic opportunities in high-potential markets.

• Indian diagnostic market forecast at 10–12% CAGR over the next five years, supported by preventive care, chronic disease prevalence and technology adoption.